Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 10/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19358788 | 0.84 | SETD7 (0.37) | LMNAGLAL3MBTL1TSHRP2RY12 | |
| SCHEMBL19358789 | 0.81 | DTYMK (0.43) | LMNAGLAL3MBTL1 | |
| SCHEMBL29480889 | 0.81 | DTYMK (0.43) | LMNAGLAL3MBTL1 | |
| SCHEMBL21835622 | 0.81 | LMNA (0.35) | LMNAGLAL3MBTL1MEN1KMT2A | |
| SCHEMBL25694835 | 0.78 | L3MBTL1 (0.51) | LMNAGLAL3MBTL1MEN1KMT2A | |
| SCHEMBL19369432 | 0.76 | LMNA (0.42) | LMNAGLAL3MBTL1MEN1KMT2A | |
| SCHEMBL31579034 | 0.71 | CNR2 (0.44) | MEN1 | |
| SCHEMBL20847265 | 0.70 | CNR2 (0.36) | — | |
| SCHEMBL29480900 | 0.70 | CNR2 (0.36) | — | |
| SCHEMBL19358796 | 0.70 | CNR2 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11944627-B2 | Methods for treating hematological malignancies and Ewing's sarcoma | KURA ONCOLOGY, INC. (US) | 2024-04-02 | — | — | US | disclosed |
| US-20230405008-A1 | TREATMENT OF HEMATOLOGICAL MALIGNANCIES WITH INHIBITORS OF MENIN | KURA ONCOLOGY, INC. | 2023-12-21 | — | — | US | disclosed |
| EP-4219449-A2 | SUBSTITUTED INDOLE DERIVATIVES AND METHODS OF PREPARATION THEREOF | Kura Oncology, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| US-11673898-B2 | Substituted inhibitors of menin-MLL and methods of use | KURA ONCOLOGY, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-20230095934-A1 | TREATMENT OF HEMATOLOGICAL MALIGNANCIES WITH INHIBITORS OF MENIN | KURA ONCOLOGY, INC. | 2023-03-30 | — | — | US | disclosed |
| EP-3429591-B1 | SUBSTITUTED THIENO[2,3-D]PYRIMIDINE DERIVATIVES AS INHIBITORS OF MENIN-MLL AND METHODS OF USE | KURA ONCOLOGY INC (US) | 2023-03-15 | — | — | EP | disclosed |
| US-20230026872-A1 | METHODS FOR TREATING HEMATOLOGICAL MALIGNANCIES AND EWING'S SARCOMA | KURA ONCOLOGY, INC. | 2023-01-26 | — | — | US | disclosed |
| US-20210101908-A1 | SUBSTITUTED INHIBITORS OF MENIN-MLL AND METHODS OF USE | KURA ONCOLOGY, INC. | 2021-04-08 | — | — | US | disclosed |
| US-10781218-B2 | Substituted inhibitors of menin-MLL and methods of use | KURA ONCOLOGY, INC. (US) | 2020-09-22 | — | — | US | disclosed |
| EP-3601249-A1 | METHODS FOR TREATING HEMATOLOGICAL MALIGNANCIES AND EWING'S SARCOMA | Kura Oncology, Inc. (US) | 2020-02-05 | — | — | EP | disclosed |
| US-20190092784-A1 | SUBSTITUTED INHIBITORS OF MENIN-MLL AND METHODS OF USE | KURA ONCOLOGY, INC. | 2019-03-28 | — | — | US | disclosed |
| EP-3429591-A1 | SUBSTITUTED INHIBITORS OF MENIN-MLL AND METHODS OF USE | Kura Oncology, Inc. (US) | 2019-01-23 | — | — | EP | disclosed |
| WO-2018175746-A1 | METHODS FOR TREATING HEMATOLOGICAL MALIGNANCIES AND EWING'S SARCOMA | KURA ONCOLOGY, INC. (US) | 2018-09-27 | — | — | WO | disclosed |
| WO-2018106820-A1 | METHODS OF PROMOTING BETA CELL PROLIFERATION | KURA ONCOLOGY, INC. (US) | 2018-06-14 | — | — | WO | disclosed |
| WO-2017161028-A1 | SUBSTITUTED INHIBITORS OF MENIN-MLL AND METHODS OF USE | KURA ONCOLOGY, INC. (US) | 2017-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230026872-A1 | METHODS FOR TREATING HEMATOLOGICAL MALIGNANCIES AND EWING'S SARCOMA | MEN1, DIAPH1, EWSR1 | P2RX7 3829/4885LMNA 401/4885GLA 1881/4885 |
| US-20190092784-A1 | SUBSTITUTED INHIBITORS OF MENIN-MLL AND METHODS OF USE | MLLT1, MEN1, MLLT3 | P2RX7 4842/4885LMNA 931/4885GLA 4010/4885 |
| US-20210101908-A1 | SUBSTITUTED INHIBITORS OF MENIN-MLL AND METHODS OF USE | MLLT1, MEN1, MLLT3 | P2RX7 4842/4885LMNA 931/4885GLA 4010/4885 |
| US-20230405008-A1 | TREATMENT OF HEMATOLOGICAL MALIGNANCIES WITH INHIBITORS OF MENIN | MEN1, MCL1, XPOT | P2RX7 3977/4885LMNA 115/4885GLA 2333/4885 |
| US-11673898-B2 | Substituted inhibitors of menin-MLL and methods of use | MLLT1, MEN1, MLLT3 | P2RX7 4844/4885LMNA 907/4885GLA 3877/4885 |
| US-20230095934-A1 | TREATMENT OF HEMATOLOGICAL MALIGNANCIES WITH INHIBITORS OF MENIN | MEN1, MCL1, XPOT | P2RX7 3977/4885LMNA 115/4885GLA 2333/4885 |
| US-10781218-B2 | Substituted inhibitors of menin-MLL and methods of use | MLLT1, MEN1, MLLT3 | P2RX7 4862/4885LMNA 830/4885GLA 3580/4885 |
| US-11944627-B2 | Methods for treating hematological malignancies and Ewing's sarcoma | MEN1, DIAPH1, EWSR1 | P2RX7 3829/4885LMNA 401/4885GLA 1881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.